Indian biotechnology company Immuneel Therapeutics has secured ₹100 crore (approximately $10.5 million) in a Series B funding round, attracting participation from both new and existing investors as it accelerates the development and commercialization of advanced cancer therapies.
The latest funding round saw investments from Singularity AMC, Rainmatter by Zerodha, and several high-net-worth individuals. Existing backers including Kiran Mazumdar-Shaw, Eight Roads Ventures, and F-Prime Capital also participated in the fundraising.
The fresh capital will be used to expand manufacturing capabilities, advance the company’s pipeline of cell and gene therapies, and support international expansion across key markets in the Asia-Pacific and Middle East regions.
Strengthening India’s Position in Advanced Cancer Treatment
Founded with a vision of making cutting-edge cancer treatments more accessible and affordable, Immuneel Therapeutics is focused on developing next-generation cell and gene therapies for patients battling complex cancers.
The company is among a growing number of Indian biotechnology firms working to build globally competitive healthcare solutions while reducing the cost barriers often associated with advanced therapies.
Commenting on the funding round, Immuneel founder Kiran Mazumdar-Shaw emphasized the company’s mission of expanding access to innovative treatments.
She noted that advanced cell therapies should not be limited to a small patient population or restricted to developed markets and highlighted India’s potential to become a global hub for affordable and scalable cell therapy innovation.
Expanding CAR-T Therapy Capabilities
Immuneel has been gaining attention for its work in CAR-T (Chimeric Antigen Receptor T-cell) therapy, an advanced form of personalized cancer treatment that uses a patient’s own immune cells to target and destroy cancer cells.
The company recently launched Qartemi, which it describes as India’s first approved CAR-T cell therapy designed for patients suffering from Non-Hodgkin Lymphoma and leukemia.
The commercialization of Qartemi represents a significant milestone for India’s biotechnology sector, demonstrating the country’s growing capabilities in advanced cancer treatment and precision medicine.
According to Immuneel, the successful launch has validated its ability to deliver world-class CAR-T outcomes at significantly lower costs compared to similar treatments available in Western markets.
Funding to Accelerate Global Expansion
Immuneel’s leadership believes the latest funding round will help accelerate its global ambitions.
The company plans to strengthen its presence across international markets while continuing to build a pipeline of next-generation cell therapies aimed at addressing unmet medical needs.
The startup is already collaborating with healthcare partners in Australia and Southeast Asia as part of its strategy to expand access to advanced cancer treatments beyond India.
With rising global demand for personalized medicine and immunotherapy solutions, the company sees significant opportunities to scale its platform internationally.
Building a Global Cell Therapy Platform from India
Founded in 2018 by Kiran Mazumdar-Shaw, Siddhartha Mukherjee, and Kush Parwar, Bengaluru-headquartered Immuneel Therapeutics has emerged as one of India’s leading biotechnology innovators focused on cancer care.
Since inception, the company has raised more than $40 million in funding, including a $15 million Series A round completed in 2022 with support from investors such as Eight Roads Ventures, True North, and F-Prime Capital.
The company is focused on building an integrated ecosystem that combines scientific research, clinical development, advanced manufacturing, and patient access.
Its long-term goal is to establish India as a globally recognized center for cell and gene therapy innovation while making advanced treatments more affordable and accessible.
India’s Biotech Sector Continues to Attract Investor Interest
The funding round comes amid increasing investor interest in India’s biotechnology and healthcare innovation ecosystem.
Advances in immunotherapy, precision medicine, gene editing, and cell therapy are creating new opportunities for startups developing specialized treatments for complex diseases.
As healthcare systems worldwide seek more effective and personalized treatment options, companies like Immuneel are positioned to play a growing role in shaping the future of cancer care.
With fresh capital in place, expanded manufacturing plans, and a growing international footprint, Immuneel Therapeutics is preparing for its next phase of growth while strengthening India’s position in the global biotechnology landscape.
Ruchi Kumar is the associate editor at Entrepreneur News Network and TVW News India, where she leads editorial strategy, brand storytelling, and startup ecosystem coverage. With a strong focus on innovation, business, and marketing insights, he curates impactful narratives that spotlight India’s evolving entrepreneurial landscape. She has written extensively on fintech, AI and emerging startups.